Cited by 204SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 epidemiological studies

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021

Open access

Tenforde, Mark W., Self, Wesley H., Naioti, Eric A., Ginde, Adit A., Douin, David J., Olson, Samantha M., Talbot, H. Keipp, Casey, Jonathan D., Mohr, Nicholas M., Zepeski, Anne, Gaglani, Manjusha, McNeal, Tresa, Ghamande, Shekhar, Shapiro, Nathan I., Gibbs, Kevin W., Files, D. Clark, Hager, David N., Shehu, Arber, Prekker, Matthew E., Erickson, Heidi L., Gong, Michelle N., Mohamed, Amira, Henning, Daniel J., Steingrub, Jay S., Peltan, Ithan D., Brown, Samuel M., Martin, Emily T., Monto, Arnold S., Khan, Akram, Hough, Catherine L., Busse, Laurence W., ten Lohuis, Caitlin C., Duggal, Abhijit, Wilson, Jennifer G., Gordon, Alexandra June, Qadir, Nida, Chang, Steven Y., Mallow, Christopher, Rivas, Carolina, Babcock, Hilary M., Kwon, Jennie H., Exline, Matthew C., Halasa, Natasha, Chappell, James D., Lauring, Adam S., Grijalva, Carlos G., Rice, Todd W., Jones, Ian D., Stubblefield, William B., Baughman, Adrienne, Womack, Kelsey N., Lindsell, Christopher J., Hart, Kimberly W., Zhu, Yuwei, Stephenson, Meagan, Schrag, Stephanie J., Kobayashi, Miwako, Verani, Jennifer R., Patel, Manish M., IVY Network Investigators, IVY Network, Calhoun, Nicole, Murthy, Kempapura, Herrick, Judy, McKillop, Amanda, Hoffman, Eric, Zayed, Martha, Smith, Michael, Settele, Natalie, Ettlinger, Jason, Priest, Elisa, Thomas, Jennifer, Arroliga, Alejandro, Beeram, Madhava, Kindle, Ryan, Kozikowski, Lori-Ann, De Souza, Lesley, Ouellette, Scott, Thornton-Thompson, Sherell, Tyler, Patrick, Mehkri, Omar, Ashok, Kiran, Gole, Susan, King, Alexander, Poynter, Bryan, Stanley, Nicholas, Hendrickson, Audrey, Maruggi, Ellen, Scharber, Tyler, Jorgensen, Jeffrey, Bowers, Robert, King, Jennifer, Aston, Valerie, Armbruster, Brent, Rothman, Richard E., Nair, Rahul, Chen, Jen-Ting (Tina), Karow, Sarah, Robart, Emily, Maldonado, Paulo Nunes, Khan, Maryiam, So, Preston, Levitt, Joe, Perez, Cynthia, Visweswaran, Anita, Roque, Jonasel, Rivera, Adreanne, Frankel, Trevor, Howell, Michelle, Friedel, Jennifer, Goff, Jennifer, Huynh, David, Tozier, Michael, Driver, Conner, Carricato, Michael, Foster, Alexandra, Nassar, Paul, Stout, Lori, Sibenaller, Zita, Walter, Alicia, Mares, Jasmine, Olson, Logan, Clinansmith, Bradley, Rivas, Carolina, Gershengorn, Hayley, McSpadden, EJ, Truscon, Rachel, Kaniclides, Anne, Thomas, Lara, Bielak, Ramsay, Valvano, Weronika Damek, Fong, Rebecca, Fitzsimmons, William J., Blair, Christopher, Valesano, Andrew L., Gilbert, Julie, Crider, Christine D., Steinbock, Kyle A., Paulson, Thomas C., Anderson, Layla A., Kampe, Christy, Johnson, Jakea, McHenry, Rendie, Blair, Marcia, Conway, Douglas, LaRose, Mary, Landreth, Leigha, Hicks, Madeline, Parks, Lisa, Bongu, Jahnavi, McDonald, David, Cass, Candice, Seiler, Sondra, Park, David, Hink, Tiffany, Wallace, Meghan, Burnham, Carey-Ann, Arter, Olivia G.·2021·MMWR. Morbidity and Mortality Weekly Report

DOI 10.15585/mmwr.mm7034e2PMC PMC8389395

Open this paper in CoChat — free account Open PDF

Abstract

Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination; longer follow-up is needed to assess durability of protection. In an evaluation at 21 hospitals in 18 states, the duration of mRNA vaccine (Pfizer-BioNTech or Moderna) effectiveness (VE) against COVID-19-associated hospitalizations was assessed among adults aged ≥18 years. Among 3,089 hospitalized adults (including 1,194 COVID-19 case-patients and 1,895 non-COVID-19 control-patients), the median age was 59 years, 48.7% were female, and 21.1% had an immunocompromising condition. Overall, 141 (11.8%) case-patients and 988 (52.1%) controls were fully vaccinated (defined as receipt of the second dose of Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines ≥14 days before illness onset), with a median interval of 65 days (range = 14-166 days) after receipt of second dose. VE against COVID-19-associated hospitalization during the full surveillance period was 86% (95% confidence interval [CI] = 82%-88%) overall and 90% (95% CI = 87%-92%) among adults without immunocompromising conditions. VE against COVID-19- associated hospitalization was 86% (95% CI = 82%-90%) 2-12 weeks and 84% (95% CI = 77%-90%) 13-24 weeks from receipt of the second vaccine dose, with no significant change between these periods (p = 0.854). Whole genome sequencing of 454 case-patient specimens found that 242 (53.3%) belonged to the B.1.1.7 (Alpha) lineage and 74 (16.3%) to the B.1.617.2 (Delta) lineage. Effectiveness of mRNA vaccines against COVID-19-associated hospitalization was sustained over a 24-week period, including among groups at higher risk for severe COVID-19; ongoing monitoring is needed as new SARS-CoV-2 variants emerge. To reduce their risk for hospitalization, all eligible persons should be offered COVID-19 vaccination.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.15585/mmwr.mm7034e2

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
Turner, J. S., O’Halloran, J. A., Kalaidina, E., Kim, W., Schmitz, A. J., Zhou, J. Q., Lei, T., Thapa, M., Chen, R. E., Case, J. B., et al. (2021) · Nature · doi:10.1038/s41586-021-03738-2 · Cited by 831
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J. K., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107058 · Cited by 482
Self-citation
Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
Tenforde, M. W., Olson, S. M., Self, W. H., Talbot, H. K., Lindsell, C. J., Steingrub, J. S., Shapiro, N. I., Ginde, A. A., Douin, D. J., Prekker, M. E., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7018e1 · Cited by 286
Self-citation
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Cromer, D., Juno, J. A., Khoury, D., Reynaldi, A., Wheatley, A. K., Kent, S. J., & Davenport, M. P. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00550-x · Cited by 265
Waning Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2015–2016 to 2018–2019, United States Hospitalized Adult Influenza Vaccine Effectiveness Network
Ferdinands, J. M., Gaglani, M., Martin, E. T., Monto, A. S., Middleton, D. B., Silveira, F. P., Talbot, H. K., Zimmerman, R. K., & Patel, M. M. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab045 · Cited by 59
Self-citation
Effectiveness of influenza vaccination on influenza-associated hospitalisations over time among children in Hong Kong: a test-negative case-control study
Feng, S., Chiu, S. S. S., Chan, E. L. Y., Kwan, M. Y. W., Wong, J. S. C., Leung, C., Lau, Y. C., Sullivan, S. G., Peiris, M. J. S., & Cowling, B. J. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30419-3 · Cited by 39

Flagged first, then by citations

Show all 8 references

Research works printed but not linked: 1

Tenforde, Clin Infect Dis

Sorted by citations

Items 101–200 of 202

Reduced Odds of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Vaccination Among New York City Adults, July 2021–November 2021
Levin‐Rector, A., Firestein, L., McGibbon, E., Sell, J. L., Lim, S., Lee, E. H., Weiss, D., Geevarughese, A., Zucker, J. R., & Greene, S. K. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac380 · Cited by 14
Impact of COVID-19 vaccination status on hospitalization and disease severity: A descriptive study in Nagasaki Prefecture, Japan
Cai, G., Liu, S., Lu, Y., Takaki, Y., Matsumoto, F., Yoshikawa, A., Taguri, T., Xie, J., Arima, K., Mizukami, S., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2322795 · Cited by 13
COVID‐19 vaccine effectiveness against hospitalization due to SARS‐CoV‐2: A test‐negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain
Mazagatos, C., Delgado‐Sanz, C., Monge, S., Pozo, F., Oliva, J. A., Sandonis, V., Gandarillas, A., Rubio, C. Q., Ruiz‐Sopeña, C., García, V. G., et al. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13026 · Cited by 12
Antispike Immunoglobulin-G (IgG) Titer Response of SARS-CoV-2 mRNA-Vaccine (BNT162b2): A Monitoring Study on Healthcare Workers
Inchingolo, A. D., Malcangi, G., Ceci, S., Patano, A., Corriero, A., Azzollini, D., Marinelli, G., Coloccia, G., Piras, F., Barile, G., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102402 · Cited by 12
Vaccinating Children against COVID-19: Commentary and Mathematical Modeling
Hawkes, M., & Good, M. F. (2022) · mBio · doi:10.1128/mbio.03789-21 · Cited by 12
Characteristics of Reported Deaths Among Fully Vaccinated Persons With Coronavirus Disease 2019—United States, January–April 2021
Watkins, L. F., Mitruka, K., Dorough, L., Bressler, S. S., Kugeler, K. J., Sadigh, K. S., Birhane, M. G., Nolen, L. D., & Fischer, M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac066 · Cited by 11
An outpatient model of care for COVID ‐19 infected kidney transplant patients – The hospital‐at‐home
Liew, I. T., Tan, W. J. M., Ho, Q. Y., Chung, S. J., Thangaraju, S., Yong, J., Ng, E., He, X., Kwan, N., & Kee, T. Y. S. (2023) · Nephrology · doi:10.1111/nep.14155 · Cited by 11
Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis
Yin, J., Chen, Y., Li, Y., Zhang, X., & Wang, C. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2119763 · Cited by 11
Selection Effects and COVID-19 Mortality Risk after Pfizer vs. Moderna Vaccination: Evidence from Linked Mortality and Vaccination Records
Atanasov, V. A., Barreto, N., Whittle, J., Meurer, J., Weston, B. W., Luo, Q., Yuan, A. Y., Franchi, L., Zhang, R., & Black, B. S. (2023) · Vaccines · doi:10.3390/vaccines11050971 · Cited by 11
Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease
Bansal, D., Abdulmajeed, J., Yassin, E., Al-Shamali, M. H. M. A., Albayat, S. S., Himatt, S. M., Cyprian, F. S., Chivese, T., Mundodan, J. M., Khogali, H., et al. (2022) · Vaccines · doi:10.3390/vaccines10071036 · Cited by 10
COVID-19 Vaccine Reactogenicity and Vaccine Attitudes Among Children and Parents/Guardians After Multisystem Inflammatory Syndrome in Children or COVID-19 Hospitalization: September 2021—May 2022
Yousaf, A. R., Kunkel, A., Abrams, J. Y., Shah, A. B., Hammett, T. A., Arnold, K. E., Beltran, Y., Laham, F. R., Kao, C. M., Hunstad, D. A., et al. (2022) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003803 · Cited by 10
Study of humoral and cellular immunity in vaccinated with mRNA‐1273
Gutiérrez‐Bautista, J. F., López‐Nevot, M. Á., Gómez-Vicente, E., Quesada, T., Marín, E. M., Rodríguez, A. I. E., Rodríguez, A. I. E., Rodríguez‐Granger, J., Cobo, F., & Sampedro, A. (2022) · Apmis · doi:10.1111/apm.13215 · Cited by 10
Enhancer RNA AL928768.3 from the IGH Locus Regulates MYC Expression and Controls the Proliferation and Chemoresistance of Burkitt Lymphoma Cells with IGH/MYC Translocation
Stasevich, E. M., Uvarova, A. N., Murashko, M. M., Khabusheva, E., Sheetikov, S. A., Prassolov, V., Kuprash, D. V., Демин, Д. Э., & Schwartz, A. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094624 · Cited by 10
Prerequisite for COVID-19 Prediction: A Review on Factors Affecting the Infection Rate
Tang, S. G. H., Hadi, M. H. H., Arsad, S. R., Ker, P. J., Ramanathan, S., Afandi, N. A. M., Afzal, M. M., Yaw, M. W., Krishnan, P. S., Chen, C. P., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192012997 · Cited by 10
The importance of combining serological testing with RT-PCR assays for efficient detection of COVID-19 and higher diagnostic accuracy
Alamri, S. S., Alsaieedi, A., Khouqeer, Y., Afeef, M. A., Alharbi, S. O., Algaissi, A. A., Alghanmi, M. S., Altorki, T. A., Zawawi, A., Alfaleh, M. A., et al. (2023) · PeerJ · doi:10.7717/peerj.15024 · Cited by 10
On the Delta Plus Variant of SARS-CoV-2
Chowdhury, S., & Bappy, M. H. (2021) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2021.3.6.1134 · Cited by 9
Vaccine third dose and cancer patients: necessity or luxury?
Παππάς, Γ., Saloustros, E. S., Boutis, A. L., Tsoukalas, N., Nikolaou, M., Christopoulou, A. N., Agelaki, S., Boukovinas, I., Ardavanis, A., & Saridaki, Z. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100306 · Cited by 9
Persistent humoral immune response in youth throughout the COVID-19 pandemic: prospective school-based cohort study
Raineri, A., Radtke, T., Rueegg, S., Haile, S. R., Menges, D., Ballouz, T., Ulytė, A., Fehr, J. S., Llanas-Cornejo, D., Pantaleo, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43330-y · Cited by 9
Modeling the Influence of Vaccine Administration on COVID-19 Testing Strategies
Forde, J. E., & Ciupe, S. M. (2021) · Viruses · doi:10.3390/v13122546 · Cited by 9
COVID-19 Infection Rates in Vaccinated and Unvaccinated Inmates: A Retrospective Cohort Study
Ko, L., Malet, G., Chang, L. L., Nguyen, H. C., & Mayes, R. (2023) · Cureus · doi:10.7759/cureus.44684 · Cited by 9
Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021
Vitek, M. G., Klavs, I., Učakar, V., Serdt, M., Mrzel, M., Vrh, M., & Fafangel, M. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.1.2101110 · Cited by 9
Real-Time RT-PCR Allelic Discrimination Assay for Detection of N501Y Mutation in the Spike Protein of SARS-CoV-2 Associated with B.1.1.7 Variant of Concern
Abdulnoor, M., Eshaghi, A., Perusini, S. J., Broukhanski, G., Corbeil, A., Cronin, K. I., Fittipaldi, N., Forbes, J. D., Guthrie, J. L., Kus, J. V., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00681-21 · Cited by 9
Estimating COVID-19 Vaccination and Booster Effectiveness Using Electronic Health Records From an Academic Medical Center in Michigan
Roberts, E., Gu, T., Wagner, A. L., Mukherjee, B., & Fritsche, L. G. (2022) · AJPM Focus · doi:10.1016/j.focus.2022.100015 · Cited by 9
The Impact of CoronaVac Vaccination on 28-day Mortality Rate of Critically Ill Patients with COVID-19 in Türkiye
Gül, F., Kasapoğlu, U. S., Sabaz, M. S., Ay, P., Oktay, B. D., Çalışkan, G., Demir, N., Sayan, İ., Kabadayı, F., Altuntaş, G., et al. (2023) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2023.2023-6-90 · Cited by 8
Effectiveness of COVID-19 mRNA Vaccines in Preventing COVID-19-Associated Outpatient Visits and Hospitalizations Among American Indian and Alaska Native Persons, January–November 2021: A Test-Negative Case-Control Analysis Using Surveillance Data
Lutz, C. S., Hartman, R. M., Vigil, D. E., Britton, A., Burrage, A. B., Campbell, A. P., Close, R. M., Desnoyers, C., Dobson, J., Garcia, S., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad172 · Cited by 8
Self-citation
Reliably Assessing Duration of Protection for Coronavirus Disease 2019 Vaccines
Lin, D.-Y., Zeng, D., Gu, Y., Krause, P. R., & Fleming, T. R. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac139 · Cited by 8
Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged ≥16 Years in the United States, February–May 2021
Kim, S. S., Chung, J. R., Belongia, E. A., McLean, H. Q., King, J. P., Nowalk, M. P., Zimmerman, R. K., Balasubramani, G. K., Martin, E. T., Monto, A. S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab451 · Cited by 7
Self-citation
Assessing the dynamic impacts of non-pharmaceutical and pharmaceutical intervention measures on the containment results against COVID-19 in Ethiopia
Zhu, H., Liu, S., Zheng, W., Belay, H., Zhang, W., Qian, Y. P., Wu, Y., Delele, T. G., & Jia, P. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271231 · Cited by 7
Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: A review and case study
Meah, S., Shi, X., Fritsche, L. G., Salvatore, M., Wagner, A. L., Martin, E. T., & Mukherjee, B. (2023) · Science Advances · doi:10.1126/sciadv.adj3747 · Cited by 7
Self-citation
Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up
Adriaenssens, N., Scholtes, B., Bruyndonckx, R., Ngoc, P. V., Verbakel, J. Y. J., Sutter, A. D., Heytens, S., den Bruel, A. V., Desombere, I., Damme, P. V., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-065897 · Cited by 7
Reduced Serological Response to COVID-19 Booster Vaccine is Associated with Reduced B Cell Memory in Patients With Inflammatory Bowel Disease; VARIATION [VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON]
Doherty, J., O’Morain, N. R., Stack, R., Tosetto, M., Inzitiari, R., O’Reilly, S. R., Gu, L., Sheridan, J., Cullen, G. J., Dermott, E. M., et al. (2023) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjad065 · Cited by 8
Booster Vaccination Strategies for “Living With COVID-19”
Kim, J. E., ‍Lee, S., & Kim, H. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.896713 · Cited by 7
The Differentiation and Maintenance of SARS-CoV-2-Specific Follicular Helper T Cells
Wang, Y., Qin, T., & Ye, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.953022 · Cited by 7
Optimalisasi Strategi Komunikasi Promosi Produk melalui Manajemen Aset Digital
Sutisna, F., & Handra, T. (2023) · Jurnal Mentari Manajemen Pendidikan dan Teknologi Informasi · doi:10.33050/mentari.v2i1.348 · Cited by 6
Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study
Chen, X., Zhu, Y., Shen, L., Zhou, D., Feng, N., & Tong, Q. (2024) · Journal of Intensive Care Medicine · doi:10.1177/08850666241228841 · Cited by 6
Self-citation
The Effect of COVID-19 Vaccines on Hospital Admission and Severity of Symptoms Among COVID-19 Patients in Saudi Arabia, 2021
Alnemari, R. F., Roublah, F. A., & Bargawi, A. A. (2023) · Cureus · doi:10.7759/cureus.41067 · Cited by 6
Investigating the trend of demographic changes, mortality, clinical and paraclinical findings of patients hospitalized in the Corona ward, before and after the start of general vaccination of COVID-19
Morovatshoar, R., Hushmandi, K., Orouei, S., Saadat, S. H., & Raesi, R. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09279-z · Cited by 5
Evaluation of the COVID-19 vaccine effectiveness on the outcomes of COVID 19 disease in Iran: a test-negative case-control study
Shadmani, F. K., Moradi, G., Naghipour, M., Asadi, F. T., Ahmadi, A. R., Mirahmadizadeh, A., Haghdoost, A. A., Mesgarpour, B., Zahraei, S. M., Goya, M. M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1420651 · Cited by 5
A hybrid simulation approach for analyzing trends of infectious disease development, intervention measures and medical cost
Zhu, H., Jia, F., & Jia, F. (2025) · Journal of Simulation · doi:10.1080/17477778.2025.2488485 · Cited by 5
Impact of BNT162b2 Booster Dose on SARS-CoV-2 Anti-Trimeric Spike Antibody Dynamics in a Large Cohort of Italian Health Care Workers
Renna, L. V., Bertani, F., Podio, A., Boveri, S., Carrara, M., Pinton, A., Milani, V., Spuria, G., Nizza, A. F., Basilico, S., et al. (2023) · Vaccines · doi:10.3390/vaccines11020463 · Cited by 5
Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters
Bricker, T. L., Joshi, A., Soudani, N., Scheaffer, S. M., Patel, N., Guebre‐Xabier, M., Smith, G., Diamond, M., & Boon, A. C. M. (2024) · Journal of Virology · doi:10.1128/jvi.01206-23 · Cited by 5
Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
Akamine, C. M., & Sahly, H. M. E. (2021) · Translational research · doi:10.1016/j.trsl.2021.12.007 · Cited by 5
Evaluating COVID-19 control measures in mass gathering events with vaccine inequalities
Al‐Shaery, A. M., Hejase, B., Tridane, A., Farooqi, N. S., & Jassmi, H. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-07609-2 · Cited by 5
Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States
Layton, J. B., Lloyd, P. C., Peetluk, L. S., Jiao, Y., Djibo, D. A., Gruber, J. F., Deng, J., Bui, C. L., Lo, A., Ogilvie, R. P., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320434 · Cited by 4
Assessing the Dynamic Outcomes of Containment Strategies against COVID-19 under Different Public Health Governance Structures: A Comparison between Pakistan and Bangladesh
Zhang, W., Huggins, T. J., Zheng, W., Liu, S., Du, Z., Zhu, H., Raza, A., & Tareq, A. H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19159239 · Cited by 4
Effectiveness and Safety of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease.
Spiera, E., Ungaro, R. C., & Kornbluth, A. A. (2022) · PubMed Central · Cited by 4
Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals
Dai, Y.-C., Lin, Y.-C., Ching, L. L., Tsai, J., Ishikawa, K. M., Tsai, W.-Y., Chen, J. J., Nerurkar, V. R., & Wang, W. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04081-22 · Cited by 4
Self-citation
Efficacy of Messenger RNA–1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021
Stephenson, K. E., Marcelin, J. R., Pettifor, A. E., Janes, H., Brown, E. R., Neradilek, M. B., Yen, C., Andriesen, J. G., Grunenberg, N. A., Espy, N., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad511 · Cited by 4
Barriers and Facilitators of COVID-19 Vaccination Outreach Program in Rural India: A Qualitative Study
Kawalkar, U. G., Balkar, V., Naitam, D., Choudhari, S., Sharma, M. R., Pawar, H., & Patil, M. S. (2023) · Cureus · doi:10.7759/cureus.35800 · Cited by 4
Clinical Characteristics and Outcomes among Vaccinated and Unvaccinated Patients with Cardiovascular Disease Who Were Hospitalized for COVID-19 in Brazil: Retrospective Cohort
Sardinha, D. M., Ferreira, A. L. D. S., Guimarães, R. J. D. P. S. E., Lima, K. V. B., & Lima, L. N. G. C. (2023) · Vaccines · doi:10.3390/vaccines11040861 · Cited by 4
Impact of Vaccination and Prior Infection on SARS-CoV-2 Viral Load in Preschool Children During the Omicron Pandemic
Suzuki, M., Tokita, A., Inaba, M., Tada, Y., Shuri, K., Miura, A., Fukazawa, M., Fujioka, M., Sakai‐Tagawa, Y., Yamayoshi, S., et al. (2025) · Vaccines · doi:10.3390/vaccines13080850 · Cited by 3
In Vivo Topical and Systemic Distribution Kinetics of Liposomes with Various Properties for Application to Drug Delivery Systems
Ibaraki, H., & Kanazawa, T. (2022) · Sensors and Materials · doi:10.18494/sam3673 · Cited by 3
Effect of COVID-19 Delta (B.1.617.2) and Omicron (B.1.1.529) surges on emergency medicine physician compassion
Bowling, J. M., Campana, C., Krizo, J. A., Mangira, C., & Simon, E. L. (2022) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2022.06.035 · Cited by 3
Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study
Hamada, H., Futamura, M., Ito, H., Yamamoto, R., Yata, K., Iwatani, Y., Inoue, H., Fukatsu, N., Nagai, H., & Hasegawa, Y. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.050 · Cited by 3
Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru
Hueda-Zavaleta, M., de la Torre, J. C. G., Cáceres-DelAguila, J. A., Muro-Rojo, C., Cruz-Escurra, N. D. L., Copaja-Corzo, C., Aragón-Ayala, C. J., & Benites-Zapata, V. A. (2023) · Vaccines · doi:10.3390/vaccines11020447 · Cited by 3
Unvaxxed and unafraid: Unvaccinated Americans perceive less disease risk than do vaccinated Americans
Hauser, D., & Meier, B. P. (2023) · Social and Personality Psychology Compass · doi:10.1111/spc3.12749 · Cited by 3
Duration of protective immunity following COVID‐19 vaccination of individuals with underlying health conditions: A rapid review
Walsh, K. A., O’Donnell, H., O’Loughlin, M., Eames, H., Jiang, J., O’Brien, K. M., Broderick, N., O’Brien, K. K., Carrigan, M., Comber, L., et al. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2504 · Cited by 3
mRNA vaccination reduces the thrombotic possibility in COVID-19: Inflammation risk estimates
Al-Sammarraie, M. R., Al-Sammarraie, M. R. H., Azaiez, F. D., Al-Rubae, Z. M. M., Litaiem, H., & Taay, Y. M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112776 · Cited by 3
COVID-19 Vaccines Effectiveness and Safety in Trinidad and Tobago: A Systematic Review and Meta-Analysis
Justiz-Vaillant, A. A., Roopnarine, K., Solomon, S., Phillips, A., Salandy, S., Subero, A., Seepersad, S., Span, N., Ramnath, P., Ramnarine, A., et al. (2025) · Microorganisms · doi:10.3390/microorganisms13010135 · Cited by 3
Effectiveness of and Immune Responses to SARS-CoV-2 mRNA Vaccines and Their Mechanisms
Gohda, E. (2022) · Journal of Disaster Research · doi:10.20965/jdr.2022.p0007 · Cited by 3
Immunogenicity and safety of the homogenous booster shot of a recombinant fusion protein vaccine (V-01) against COVID-19 in healthy adult participants primed with a two-dose regimenPreprint
Li, Y., Fang, X. D., Pei, R., Fan, R., Chen, S., Zeng, P., Ou, Z., Deng, J., Zhou, J., Sun, Z., et al. (2021) · medRxiv · doi:10.1101/2021.11.04.21265780 · Cited by 3
Special Issue: “Vaccination and Global Health”
Ma, S., Bi, Q., Liu, L., Thapa, R. J., Li, W., Liu, B., Xu, C., & Sun, C. (2024) · Vaccines · doi:10.3390/vaccines12111223 · Cited by 3
Effects of Government Mistrust and Group-Based Medical Mistrust on COVID-19 Vaccine Hesitancy Among a Sample of African Americans
Manning, M. A., Dailey, R., Levy, P., Towner, E., Cresswell, S., & Thompson, H. S. (2024) · Annals of Behavioral Medicine · doi:10.1093/abm/kaae067 · Cited by 2
A COVID-19 primer for primary care clinicians
Burkhardt, M. C., Winter, K., Alter, S. J., & Klatte, J. M. (2022) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2022.101180 · Cited by 2
COVID-19 vaccination status and its effect on outcome and disease severity
Andrews, A., Mathew, A. C., & Mathew, T. (2023) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20230016 · Cited by 2
Retrospective Analysis of Vaccinated and Unvaccinated COVID-19 Patients Treated with Monoclonal Antibodies (mAb) and Their Emergent Needs (RAVEN)
Simeunovic, G., Polega, J. R., TOOR, S. A., & Andersen, N. J. (2023) · Vaccines · doi:10.3390/vaccines11030688 · Cited by 2
Effectiveness of the Pfizer-BioNTech Vaccine against COVID-19-Associated Hospitalizations among Lebanese Adults ≥75 Years Old—Lebanon, April–May 2021
Farah, Z., Haddad, N., Naja, H. A. E., Saleh, M., Mrad, P., & Ghosn, N. (2023) · Epidemiologia · doi:10.3390/epidemiologia4020022 · Cited by 2
Efficacy of COVID-19 Vaccines against the Omicron Variant of SARS-CoV-2: A Review
Rajsri, K. S., Singh, M., & Rao, M. (2023) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2023.00023 · Cited by 2
The effect of COVID-19 vaccination status on all-cause mortality in patients hospitalised with COVID-19 in Hungary during the delta wave of the pandemic
Horváth, V. J., Békeffy, M. Z., Németh, Z., Szelke, E., Fazekas‐Pongor, V., Hajdú, N., Svébis, M. M., Pintér, J., Domján, B. A., Mészáros, S., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00931-1 · Cited by 2
Glucose control during breakthrough SARS-CoV-2 infections in vaccinated patients with type 1 diabetes
Longo, M., Scappaticcio, L., Signoriello, S., Caruso, P., Maio, A., Botta, G., Arena, S., Cirillo, P., Petrizzo, M., Bellastella, G., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111044 · Cited by 2
Co-Administration of Seasonal Quadrivalent Influenza and Covid-19 Vaccines Leads to Enhanced Immune Responses to Influenza Virus and Reduced Immune Responses to Sars-Cov-2 in Naive Mice
Abbad, A., Yueh, J., Yellin, T., Singh, G., Carreño, J. M., Clark, J. J., Muramatsu, H., Tiwari, S., Bhavsar, D., Alzua, G. P., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2025.126825 · Cited by 2
Potential protective advantage of the protein-subunit SARS-CoV-2 vaccines, MVC-CoV1901 and NVX-CoV2373, in patients with rituximab-treated immune-mediated inflammatory diseases: Real-world evidence
Lai, P.-H., Lan, T., Lu, C., & Hsieh, S. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.06.029 · Cited by 2
COVID-19 Infection and Acute Pancreas Transplant Graft Thrombosis
Thiyagarajan, U. M., Dajani, K. Z., Anderson, B. L., Bigam, D. L., & Shapiro, A. M. J. (2023) · Cureus · doi:10.7759/cureus.34087 · Cited by 1
Bolstering the Measurement of Racial Inequity of COVID-19 Vaccine Uptake
Russ, S., Bramley, J. C., Liu, Y., & Boyce, I. (2023) · Vaccines · doi:10.3390/vaccines11040876 · Cited by 1
Clinical Evolution and Risk Factors in Patients Infected during the First Wave of COVID-19: A Two-Year Longitudinal Study
Rescalvo-Casas, C., Pérez‐Tanoira, R., Fernández-Villegas, R., Hernando-Gozalo, M., Seijas‐Pereda, L., Pérez‐García, F., Moríñigo, H. M., Gómez-Herruz, P., Arroyo, T., González, R., et al. (2023) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed8070340 · Cited by 1
How to Explain Vaccination to Your Unvaccinated Patients
Shafer, S. L. (2021) · ASA Monitor · doi:10.1097/01.asm.0000798480.52197.38 · Cited by 1
Performance of Rapid Antigen Tests Based on Symptom Onset and Close Contact Exposure: A secondary analysis from the Test Us At Home prospective cohort studyPreprint
Herbert, C., Wang, B., Lin, H., Hafer, N., Pretz, C., Stamegna, P., Tarrant, S., Hartin, P., Ferranto, J., Behar, S., et al. (2023) · medRxiv · doi:10.1101/2023.02.21.23286239 · Cited by 1
Even Two Doses of COVID-19 Vaccine Afforded Some Protection to Immunocompromised Patients
Kaul, D. R. (2021) · Journal watch · doi:10.1056/nejm-jw.na53983
Big Data and Behavioral Economics in Infectious Diseases
Jhaveri, R. R. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.09.006
Effectiveness of Vaccination against Reported SARS-CoV-2 Infection in United States Coast Guard Personnel between May and August 2021: A Time-Series AnalysisPreprint
Iskander, J. K., Frost, J., Russell, S., Ahluwalia, J. S., Ward, E., Steiner, S., Thomas, D. L., & Michaud, P. R. (2021) · medRxiv · doi:10.1101/2021.11.19.21266537
mRNA SARS-CoV2 Specific and Childhood Vaccines against Covid-19 Pandemic
Yazgan, İ. (2021) · Türk doğa ve fen dergisi :/Türk doğa ve fen dergisi · doi:10.46810/tdfd.994622
Outbreak of COVID-19 among vaccinated and unvaccinated homeless shelter residents — Sonoma County, California, July 2021Preprint
Bukatko, A. R., Lobato, M. N., Mosites, E. M., Stainken, C., Reihl, K., Deldari, M., Bell, J., Morris, M. K., Wadford, D. A., Harriman, K. H., et al. (2021) · medRxiv · doi:10.1101/2021.12.07.21267204
Samson + Delilah: Pembacaan Ulang Karya Rubens Dalam Konteks Liminalitas Melalui Pendekatan Fenomenologis
Sungkar, A., Dewi, C. S., & Susanto, M. R. (2022) · Jurnal Senirupa Warna (JSRW)/Jurnal Seni Rupa Warna · doi:10.36806/.v10i1.141
Observation of SARS-CoV-2 genome characteristics and clinical manifestations within eight family clusters from GH and GK clades in Jakarta, Indonesia
Ibrahim, F., Natasha, A., Yasmon, A., Fithriyah, F., Karuniawati, A., Rahmawaty, R. G., Saharman, Y. R., & Sudarmono, P. P. (2022) · F1000Research · doi:10.12688/f1000research.122019.2
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US
Kao, Y., Wei, J. C., & Yeh, C. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.3045
Genetic-Based Vaccine Vectors
Weiner, D. B., Jansen, K. U., & Villafana, T. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00068-2
Low Risk of SARS-CoV-2 Reinfection for Fully or Boosted mRNA Vaccinated Subjects in Sicily: A Population-Based Study Using Real-World Data
Maniscalco, L., Genovese, D., Ravazzolo, B., Vella, G., Sparacia, B., Vitale, F. M., Matranga, D., & Amodio, E. (2023) · Vaccines · doi:10.3390/vaccines11121757
COVID-19 vaccine hesitancy, safety and effectiveness
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4812-7
ASSESSMENT OF MORTALITY RISKS FROM COVID-19 IN HOSPITALISED VACCINATED PATIENTS AND PATIENTS AFTER A PREVIOUS ILLNESS DEPENDING ON AGE
Riaba, O. V., Golubovska, O. A., & Chalyy, K. A. (2024) · Medical Science of Ukraine (MSU) · doi:10.32345/2664-4738.3.2024.07
A Big Data Optimization Approach for Estimating the Time-Dependent Effectiveness Profiles Against Hospitalization for Double- and Single-Dose Schemes: Study Case, COVID-19 in Elderly Mexicans
González-Sánchez, Ó. A., González-Ortiz, L. J., Sánchez-Peña, M. J., & Pulido, H. G. (2025) · Vaccines · doi:10.3390/vaccines13040363
Natural, vaccine-induced immunity and the probability of experiencing SARS-CoV-2 infection in a household cohort in Rio de Janeiro
da Silva, M. F. B., Guaraldo, L., Bastos, L. S., Santos, H. F. P., Espíndola, O. D. M., Resende, P. C., Penetra, S. L. S., de Pina-Costa, A., Moraes, I. C. V., Calvet, G. A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-97289-5
Association of vaccination status and immunosuppression with mortality of SARS-CoV-2 infection in patients with fibrotic interstitial lung disease
Donohoe, K., Johannson, K. A., Manganas, H., Marcoux, V. S., & Ryerson, C. J. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-003008
Are older adults living with HIV more susceptible to omicron infection compared to their HIV-negative peers in China: a cross-sectional study
Yang, J., Strodl, E. S., Xu, H., Jiang, H., Chu, K., Tan, S., Ye, Z., Shi, H., Chen, W., & Tong, F. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1685868
Additional file 1 of Investigating the trend of demographic changes, mortality, clinical and paraclinical findings of patients hospitalized in the Corona ward, before and after the start of general vaccination of COVID-19
Morovatshoar, R., Hushmandi, K., Orouei, S., Saadat, S. H., & Raesi, R. (2024) · Figshare · doi:10.6084/m9.figshare.25815149
Additional file 1 of Association between vaccination rates and COVID-19 health outcomes in the United States: a population-level statistical analysis
Du, H., Saiyed, S., & Gardner, L. (2024) · Figshare · doi:10.6084/m9.figshare.26669466
the neural based of predictive styles along the autism-schizophrenia continuum
Tarasi, L. (2024) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.48676/unibo/amsdottorato/11519
Additional file 2 of Investigating the trend of demographic changes, mortality, clinical and paraclinical findings of patients hospitalized in the Corona ward, before and after the start of general vaccination of COVID-19
Morovatshoar, R., Hushmandi, K., Orouei, S., Saadat, S. H., & Raesi, R. (2024) · Figshare · doi:10.6084/m9.figshare.25815613
Additional file 4 of Investigating the trend of demographic changes, mortality, clinical and paraclinical findings of patients hospitalized in the Corona ward, before and after the start of general vaccination of COVID-19
Morovatshoar, R., Hushmandi, K., Orouei, S., Saadat, S. H., & Raesi, R. (2024) · Figshare · doi:10.6084/m9.figshare.26719707
Additional file 3 of Investigating the trend of demographic changes, mortality, clinical and paraclinical findings of patients hospitalized in the Corona ward, before and after the start of general vaccination of COVID-19
Morovatshoar, R., Hushmandi, K., Orouei, S., Saadat, S. H., & Raesi, R. (2024) · Figshare · doi:10.6084/m9.figshare.26719704
Long COVID with Symptoms Persisting for More than Six Months in Unvaccinated Patients: Investigation of Biochemical Changes Associated with Chronic Manifestations
Torres, M. D. F., Davanço, G. Y., Destro, I. D. P., Murad, N., da Veiga, G. L., Reis, P. H. A., Martins, R. D. L. B., Alves, B. D. C. A., Raimundo, R. D., Zangirolami-Raimundo, J., et al. (2026) · COVID · doi:10.3390/covid6030039

Protection of mRNA vaccines against hospitalized COVID-19 in adults over the first year following authorization in the United States
Tenforde, M. W., Self, W. H., Zhu, Y., Naioti, E. A., Gaglani, M., Ginde, A. A., Jensen, K., Talbot, H. K., Casey, J. D., Mohr, N. M., et al. (2023) · eScholarship (California Digital Library) · Cited by 4
Self-citation
Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States
Tenforde, M. W., Self, W. H., Zhu, Y., Naioti, E. A., Gaglani, M., Ginde, A. A., Jensen, K., Talbot, H. K., Casey, J. D., Mohr, N. M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac381 · Cited by 21
Self-citation
Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States
Tenforde, M. W., Patel, M. M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A. E., Gaglani, M., McNeal, T., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab687 · Cited by 243
Self-citation
Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans — Five Veterans Affairs Medical Centers, United States, February 1–September 30, 2021
Bajema, K. L., Dahl, R. M., Evener, S. L., Prill, M. M., Rodriguez‐Barradas, M. C., Marconi, V. C., Beenhouwer, D. O., Holodniy, M., Lucero-Obusan, C. A., Brown, S. T., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7049a2 · Cited by 72
Self-citation
Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United StatesPreprint
Tenforde, M. W., Patel, M. M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A. E., Gaglani, M., McNeal, T., et al. (2021) · medRxiv · doi:10.1101/2021.07.08.21259776 · Cited by 108
Self-citation

See all

Authors: Tenforde, M. W., Self, W. H., Naioti, E. A., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Gaglani, M., McNeal, T., Ghamande, S., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., Gong, M. N., Mohamed, A., Henning, D. J., Steingrub, J. S., Peltan, I. D., Brown, S. M., Martin, E. T., Monto, A. S., Khan, A., Hough, C. L., Busse, L. W., ten Lohuis, C. C., Duggal, A., Wilson, J. G., Gordon, A. J., Qadir, N., Chang, S. Y., Mallow, C., Rivas, C., Babcock, H. M., Kwon, J. H., Exline, M. C., Halasa, N., Chappell, J. D., Lauring, A. S., Grijalva, C. G., Rice, T. W., Jones, I. D., Stubblefield, W. B., Baughman, A., Womack, K. N., Lindsell, C. J., Hart, K. W., Zhu, Y., Stephenson, M., Schrag, S. J., Kobayashi, M., Verani, J. R., Patel, M. M., IVY Network Investigators, IVY Network, Calhoun, N., Murthy, K., Herrick, J., McKillop, A., Hoffman, E., Zayed, M., Smith, M., Settele, N., Ettlinger, J., Priest, E., Thomas, J., Arroliga, A., Beeram, M., Kindle, R., Kozikowski, L.-A., De Souza, L., Ouellette, S., Thornton-Thompson, S., Tyler, P., Mehkri, O., Ashok, K., Gole, S., King, A., Poynter, B., Stanley, N., Hendrickson, A., Maruggi, E., Scharber, T., Jorgensen, J., Bowers, R., King, J., Aston, V., Armbruster, B., Rothman, R. E., Nair, R., Chen, J.-T. (., Karow, S., Robart, E., Maldonado, P. N., Khan, M., So, P., Levitt, J., Perez, C., Visweswaran, A., Roque, J., Rivera, A., Frankel, T., Howell, M., Friedel, J., Goff, J., Huynh, D., Tozier, M., Driver, C., Carricato, M., Foster, A., Nassar, P., Stout, L., Sibenaller, Z., Walter, A., Mares, J., Olson, L., Clinansmith, B., Rivas, C., Gershengorn, H., McSpadden, E., Truscon, R., Kaniclides, A., Thomas, L., Bielak, R., Valvano, W. D., Fong, R., Fitzsimmons, W. J., Blair, C., Valesano, A. L., Gilbert, J., Crider, C. D., Steinbock, K. A., Paulson, T. C., Anderson, L. A., Kampe, C., Johnson, J., McHenry, R., Blair, M., Conway, D., LaRose, M., Landreth, L., Hicks, M., Parks, L., Bongu, J., McDonald, D., Cass, C., Seiler, S., Park, D., Hink, T., Wallace, M., Burnham, C.-A., & Arter, O. G.
Affiliations: Montefiore Medical Center (US)
Beth Israel Deaconess Medical Center (US)
Baylor Scott & White Health (US)
Baystate Medical Center (US)
Cleveland Clinic (US)
Emory University (US)
Hennepin County Medical Center (US)
Intermountain Medical Center (US)
Johns Hopkins University (US)
The Ohio State University (US)
Stanford University (US)
University of California, Los Angeles (US)
University of Colorado Hospital (US)
University of Iowa (US)
University of Miami (US)
University of Michigan (US)
University of Washington (US)
Vanderbilt University Medical Center (US)
Wake Forest University (US)
Washington University in St. Louis (US)
Corresponding author: Tenforde, Mark W.
ORCID: Tenforde, Mark W.
Self, Wesley H.
Ginde, Adit A.
Douin, David J.
Olson, Samantha M.
Talbot, H. Keipp
Casey, Jonathan D.
Mohr, Nicholas M.
Zepeski, Anne
Gaglani, Manjusha
McNeal, Tresa
Ghamande, Shekhar
Shapiro, Nathan I.
Gibbs, Kevin W.
Files, D. Clark
Hager, David N.
Shehu, Arber
Prekker, Matthew E.
Erickson, Heidi L.
Gong, Michelle N.
Mohamed, Amira
Steingrub, Jay S.
Peltan, Ithan D.
Brown, Samuel M.
Martin, Emily T.
Monto, Arnold S.
Khan, Akram
Hough, Catherine L.
Busse, Laurence W.
Duggal, Abhijit
Wilson, Jennifer G.
Gordon, Alexandra June
Qadir, Nida
Chang, Steven Y.
Mallow, Christopher
Babcock, Hilary M.
Kwon, Jennie H.
Exline, Matthew C.
Halasa, Natasha
Chappell, James D.
Lauring, Adam S.
Grijalva, Carlos G.
Rice, Todd W.
Stubblefield, William B.
Womack, Kelsey N.
Lindsell, Christopher J.
Hart, Kimberly W.
Zhu, Yuwei
Schrag, Stephanie J.
Kobayashi, Miwako
Verani, Jennifer R.
Patel, Manish M.
Murthy, Kempapura
Smith, Michael
Ettlinger, Jason
Priest, Elisa
Thomas, Jennifer
Arroliga, Alejandro
Kozikowski, Lori-Ann
Ouellette, Scott
Tyler, Patrick
Mehkri, Omar
King, Jennifer
Rothman, Richard E.
Huynh, David
Sibenaller, Zita
Gershengorn, Hayley
Truscon, Rachel
Thomas, Lara
Valvano, Weronika Damek
Fitzsimmons, William J.
Valesano, Andrew L.
Blair, Marcia
Wallace, Meghan
Burnham, Carey-Ann
Venue: MMWR. Morbidity and Mortality Weekly Report
Publisher: Centers for Disease Control MMWR Office
Published: 2021-08-27
Volume: 70
Issue: 34
Pages: 1156-1162
ISSN: 0149-2195 (ISSN-L)
1545-861X
DOI: 10.15585/mmwr.mm7034e2
PMC: PMC8389395
OpenAlex: W3195990721
Cited by: 204
References: 8
Citations by year: 2026: 1 · 2025: 10 · 2024: 22 · 2023: 43 · 2022: 86 · 2021: 42
FWCI: 15.28
Type: journal article
Language: en
Open access: diamond
doi.org
Locations: MMWR Morbidity and Mortality Weekly Report (publishedVersion)
PubMed Central (publishedVersion, public-domain)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: U.S. Department of Defense
Pfizer
Sanofi
Vanderbilt University
University of Miami
Brigham Young University
Ohio State University
Emory University
Medpace
United Therapeutics Corporation
Wake Forest University
Cleveland Clinic
University of Washington
Johns Hopkins University
Hennepin County Medical Center
Cumberland Pharmaceuticals
Regeneron Pharmaceuticals
Vanderbilt University Medical Center
Incyte
Marcus Foundation
University of Oxford
Seqirus
National Institutes of Health
Agency for Healthcare Research and Quality
University of California, Los Angeles
National Heart, Lung, and Blood Institute (T32HL087738)
National Institute of General Medical Sciences (T32GM135169)
Janssen Pharmaceuticals
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Social Sciences › Health › Vaccine Coverage and Hesitancy
Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords: mRNA vaccines, BNT162b2, Moderna vaccine, COVID-19 pandemic, vaccine effectiveness, hospitalization, immunocompromising conditions, SARS-CoV-2 variants, hospitalized adults, real-world effectiveness, whole genome sequencing
MeSH terms: COVID-19, COVID-19 Vaccines, mRNA Vaccines, Adolescent, Adult, Aged, Female, Hospitalization, Humans, Male, Middle Aged, Time Factors, United States, Vaccination, Vaccines, Synthetic, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks